A recent study has identified a potential link between high dietary salt intake and the development of a severe form of fatty liver disease in individuals who are not overweight. The research suggests that fatty liver disease, commonly associated with obesity, may arise through different biological mechanisms in lean individuals.

Researchers from Duke-NUS Medical School in Singapore and University College London developed a mouse model to investigate how high salt consumption affects liver health in the absence of obesity. They fed mice a diet known to induce fatty liver disease, supplemented with high levels of salt. The results showed that, while salt did not cause significant fat accumulation in the liver, it triggered notable inflammation and fibrosis, or scarring.

The findings indicate that lean individuals with fatty liver disease might experience liver inflammation and damage through pathways distinct from those involved in obesity-related cases. Dr. Zhou Jin of Duke-NUS Medical School, one of the lead researchers, stated that lean fatty liver disease should not be viewed as simply the same condition occurring in thinner individuals. Instead, the study suggests that high salt intake can alter liver metabolism and activate inflammatory processes independently of excess fat.

Fatty liver disease affects approximately one-third of adults in the United Kingdom and is typically linked with obesity, high cholesterol, and type 2 diabetes. The condition often remains asymptomatic but can progress to inflammation, scarring of the liver tissue, and, in severe cases, liver failure. Beyond liver disease, excessive salt intake is known to increase blood pressure, raising the risk of cardiovascular events such as heart attacks and strokes. Public health guidelines in the UK recommend an adult daily salt intake of no more than one teaspoon.

The study’s authors highlight that the distinct metabolic and inflammatory mechanisms in lean fatty liver disease may explain why treatments effective in obesity-associated cases do not always benefit lean patients. These insights underscore the need for more tailored therapeutic approaches based on an individual’s metabolic profile and disease etiology.

This research contributes to a growing recognition that fatty liver disease is a heterogeneous condition and challenges the prevailing assumption that it primarily results from obesity and fat accumulation. Further studies will be needed to determine how these findings translate to clinical care and whether reducing salt intake could benefit patients with lean fatty liver disease.